Meningitis News and Research

Latest Meningitis News and Research

FDA and PATH collaborate to advance pneumococcal vaccine development for children

The U.S. Food and Drug Administration (FDA) today announced a collaboration with PATH to advance development of a vaccine to protect children against diseases caused by Streptococcus pneumoniae (pneumococcus), especially pneumonia.

2 Feb 2010

WHO pneumonia expert honored with PACE Global Leadership Award

WHO pneumonia expert Dr. Thomas Cherian will be honored by a group of the world’s leading infectious disease experts today for his pivotal work to accelerate access to vaccines preventing pneumococcal disease, the world’s leading vaccine-preventable killer of children under age five.

31 Jan 2010

Study indicates dogs make excellent models for studying human genetic disorders

In the new Swedish-Finnish study, published in Nature Genetics, the researchers identified five loci that predispose to an SLE-related disease in Nova Scotia duck tolling retrievers.

31 Jan 2010

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill and Melinda Gates announced Friday during the World Economic Forum in Davos, Switzerland, that their foundation would commit $10 billion over the next decade to research, develop and deliver vaccines for the world's poorest countries, the New York Times reports (McNeil, 1/29). The Gateses "said they hope the commitment would spur support by governments, corporations, and other donors for vaccinations efforts," the Chronicle of Philanthropy writes (Wilhelm, 1/29).

30 Jan 2010

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world's poorest countries.

29 Jan 2010

Sinovac prices public offering at $5.75 per common share

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today that it has priced its public offering of 10,000,000 common shares at $5.75 per common share. Sinovac has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,500,000 common shares on the same terms and conditions.

28 Jan 2010

Scientists map origin of MRSA, technology could help understanding of other diseases

"Scientists have found a way to track minutely-differing strains of the 'superbug' MRSA [methicillin-resistant Staphylococcus aureus] as they spread between people and across the globe, a finding that could aid efforts to control the deadly bacteria," Reuters/ABC News reports (Kelland, 1/21).

23 Jan 2010

Men who buy fake internet drugs for ED problems face significant health risks

Men who buy fake internet drugs for erection problems can face significant risks from potentially hazardous contents and bypassing healthcare systems could leave associated problems like diabetes and high blood pressure undiagnosed.

21 Jan 2010

Sinovac Biotech announces financial update, new joint ventures and developments

Sinovac Biotech Ltd. (SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, today announced the following recent developments.

21 Jan 2010

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, today announced that it plans to sell, subject to market and other conditions, 8,650,000 common shares of the company in an underwritten public offering.

21 Jan 2010

Over 44% of internet Viagra is counterfeit

Research by UK, Swedish and American researchers shows that taking internet drugs can kill and bypassing health systems can leave life-threatening problems undiagnosed. It's estimated that 90% of counterfeit drugs are sold on the internet, 44% of internet Viagra is fake, the global sale of counterfeit drugs will reach $75 billion this year and EU seizures have risen dramatically. Counterfeit drug deaths include men who took fake erectile dysfunction drugs, pregnant women injected with fake iron for anaemia and children who took paracetamol syrup contaminated with antifreeze.

20 Jan 2010

Complications associated with pediatric cochlear implants are not rare and can often be delayed

Some complications may occur in children receiving cochlear implants, and are highly correlated with trauma to the ear area and inner ear malformation, according to a report in the January issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

19 Jan 2010

Whitley urges public to get vaccinated against H1N1 influenza virus

With several months left in the influenza season and growing supplies of vaccine, now is an opportune time to get vaccinated against the 2009 H1N1 influenza virus, says Richard Whitley, M.D., director of the University of Alabama at Birmingham (UAB) Division of Pediatric Infectious Diseases and current president of the Infectious Diseases Society of America (IDSA).

13 Jan 2010

Swedish study opens new potential for combating resistant bacteria

Neisseria meningitidis, the meningococcus, is a bacterium that can cause diseases with high fatality rates, and there has therefore been considerable concern that, like other bacteria, it might become resistant to antibiotics. But now a study from örebro University and örebro University Hospital in Sweden shows that there has not been any increase in resistant meningococci in Sweden over the last 15 years. According to researcher Sara Thulin Hedberg, the reason for this may be that it is not especially advantageous for bacteria to develop resistance.

5 Jan 2010

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

Bacteria can swim, propelling themselves through fluids using a whip-like extension called a flaggella. They can also walk, strolling along solid surfaces using little fibrous legs called pili. It is this motility that enable some pathogenic bacteria to establish the infections - such as meningitis - that cause their human hosts to get sick or even die.

4 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009

NMA urges parents to protect their children from meningococcal disease

This winter, while many parents are focused on influenza prevention, the National Meningitis Association (NMA) is urging parents to also protect their families from meningococcal disease, a deadly but potentially vaccine preventable bacterial infection.

22 Dec 2009

Survey examines disease R&D investment in 2008

According to an annual survey released Tuesday by the George Institute for International Health that looks at research and development (R&D) funding of diseases that affect the developing world, the U.S. government in 2008 "remained the single biggest contributor as it again provided almost half of the total funding but the report notes developing countries like Brazil [and] India ... were becoming a growing force," AAP/Sydney Morning Herald reports (Rose, 12/15).

17 Dec 2009

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009

Meningitis News and Research

Latest Meningitis News and Research

FDA and PATH collaborate to advance pneumococcal vaccine development for children

WHO pneumonia expert honored with PACE Global Leadership Award

Study indicates dogs make excellent models for studying human genetic disorders

At World Economic Forum, Gates Foundation announces 10-year, $10B vaccine commitment

Bill & Melinda Gates Foundation commits $10 billion for vaccine research and development

Sinovac prices public offering at $5.75 per common share

Scientists map origin of MRSA, technology could help understanding of other diseases

Men who buy fake internet drugs for ED problems face significant health risks

Sinovac Biotech announces financial update, new joint ventures and developments

SVA plans to sell 8,650,000 common shares in an underwritten public offering

Over 44% of internet Viagra is counterfeit

Complications associated with pediatric cochlear implants are not rare and can often be delayed

Whitley urges public to get vaccinated against H1N1 influenza virus

Swedish study opens new potential for combating resistant bacteria

Discovery of key process in bacterial infection could lead to new drug targets to prevent infection

Pfizer provides update on Prevnar 13

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

NMA urges parents to protect their children from meningococcal disease

Survey examines disease R&D investment in 2008

Pfizer's Prevenar 13 granted European marketing authorization

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Meningitis News and Research

Latest Meningitis News and Research

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Modular cleanrooms: Enhancing flexibility and compliance

Newsletters you may be interested in